Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 64Lung Neoplasms 27Triple Negative Breast Neoplasms 19Squamous Cell Carcinoma of Head and Neck 16Breast Neoplasms 16Small Cell Lung Carcinoma 12Parkinson Disease 4, Autosomal Dominant Lewy Body 12Ovarian Neoplasms 12Fallopian Tube Neoplasms 12Endometrial Neoplasms 11Neoplasms 9Neoplasm Metastasis 6Carcinoma 6Oropharyngeal Neoplasms 5Urinary Bladder Neoplasms 4Mouth Neoplasms 4Lung Diseases 4Laryngeal Neoplasms 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Adenocarcinoma of Lung 4Uterine Cervical Neoplasms 3Respiratory Tract Neoplasms 3Prostatic Neoplasms 3Mesothelioma 3Hypopharyngeal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Central Nervous System Neoplasms 3Carcinoma, Ovarian Epithelial 3Advanced Solid Tumors 3

Interventions

Magnetic Resonance Spectroscopy 28enzalutamide 23Specimen Handling 20apalutamide 17Androgen Antagonists 14Radiosurgery 13Radiotherapy 12Prednisone 12Docetaxel 12Abiraterone Acetate 12abiraterone 10Biopsy 10Radiation 8niraparib 6luprolide acetate gel depot 6darolutamide 6Pluvicto 6Leuprolide 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6relugolix 5gallium 68 PSMA-11 5cabazitaxel 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Nivolumab 5Gonadotropin-Releasing Hormone 5bicalutamide 4Triptorelin Pamoate 4Surveys and Questionnaires 4Radiotherapy, Intensity-Modulated 4Glutamate Carboxypeptidase II 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Carboplatin × 30 days × Clear all
NCT03934840 2026-05-26

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
61 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT06632977 2026-05-08

PREDICT

Alliance for Clinical Trials in Oncology

Phase 2 Recruiting
474 enrolled
Genitourinary

Prostatic Neoplasms

NCT05005728 2026-05-05

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Xencor, Inc.

Phase 2 Completed
72 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡